HOME >> MEDICINE >> NEWS
Only Eight Percent Of San Francisco HIV-Positive Urban Poor Receive Protease,,Inhibitors

Geneva, Switzerland -- In the first large-scale study of HIV treatment among the urban poor, University of California San Francisco AIDS researchers have found that very few of the HIV-infected poor receive drugs to combat the virus. Of those who do take anti-retroviral drugs, the researchers found a range of how well the patients adhered to their drug-taking regimens, ranging from 24 to 100 percent of prescribed levels. If subjects missed more than 10 percent of their drugs, the HIV treatment became ineffective.

The research project, called the REACH study for "Research in Access to Care in the Homeless," was started in response to concerns that the urban poor may develop resistant strains of HIV as a result of not adhering to their therapy. The UCSF team looked at how many of these people who were HIV-infected received therapy, how well they adhered to their regimens, and how the virus responded. David Bangsberg, MD, MPH, assistant professor of medicine at the UCSF AIDS Program at San Francisco General Hospital, was medical director of the study. He presented the research findings here today (July 1) at the 12th World AIDS Conference.

"This is the first study of anti-retroviral use in a population that makes up a growing portion of the HIV epidemic," said Andrew Moss, PhD, professor of epidemiology and medicine at UCSF and principal investigator. "Poor people are increasingly the main high-risk group for HIV."

Bangsberg said, "Most people think studies can't be done with the homeless because they are hard to keep track of. We found that to be untrue. Of 153 people in the study, we know where 151 of them are now, after more than a year." The UCSF team identified participants for the research project in free food lines, homeless shelters and low-income hotels and tested them for HIV infection. For those HIV-positive people on protease inhibitors, the researchers looked at three measures of adherence: self-report, random pill counts, and a digital
'"/>

Contact: Mitzi Baker
mabaker@itsa.ucsf.edu
(415) 476-2557
University of California - San Francisco
1-Jul-1998


Page: 1 2 3

Related medicine news :

1. Eight New Hartford doctoral fellows in Geriatric Social Work selected
2. Eighty five percent of practice nurses are underestimating the prevalence of insulin resistance in type 2 diabetes patients
3. UCSF And Eight Other Medical Centers Chosen For National Cancer Institutes Pediatric Brain Tumor Consortium
4. Express Scripts 1999 drug trend report: Seniors hit hardest by record 17.4-Percent prescription drug spending increase
5. New Study Finds Blacks Face 38 Percent Higher Stroke Risk
6. Osteoporosis Drug Evista (Raloxifene) Cuts Newly Diagnosed, Invasive Breast Cancer Risk By More Than 60 Percent
7. Study Finds Incidence Of Stroke Over 40 Percent Higher Than Previously Stated Figures
8. Rats Receiving Ginkgo Biloba Learn Quicker, Live 20 Percent Longer Than Controls, UB Study Finds
9. Congress of Neuological Surgeons meets in San Francisco
10. American Academy of Neurology presents 56th Annual Meeting in San Francisco, April 24 - May 1, 2004
11. NIH funds new brain imaging center at San Francisco VA Medical Center

Post Your Comments:
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... Conserve hip replacement lawsuits in U.S. District ... in response to a request from Plaintiffs’ Counsel to ... Defendant. The May 17th Order grants that request, ... be conducted. (In re: Wright Medical Technology, Inc., Conserve ...
(Date:5/21/2013)... MedMar Healing Center announces their participation ... Food Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, and ... The goal is to raise food to help area kids ... families in recent years. , “We like being able ... need,” explains Douglas Chloupek of MedMar Healing Center. “Taking part ...
(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...
(Date:5/21/2013)... 21, 2013 Today, Zane Benefits, Inc. ... FSA accounts. Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... , According to Zane Benefits’ website, the Affordable Care ... into law in 2010 and impacts many areas of ...
(Date:5/21/2013)... May 21, 2013 The American Diabetes ... people in the United States of America are affected ... at a great risk of developing peripheral neuropathy which ... lives. The ADA further goes on saying that the ... and around 2 million new cases are diagnosed every ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
(Date:5/21/2013)... N.Y. , May 21, 2013 Sanofi ... (NASDAQ: REGN) today announced that the New England ... 2a study results of dupilumab (SAR231893/REGN668) in patients with ... targeting the alpha subunit of the interleukin 4 receptor ... IL-13, drivers of Th2 (Type 2 helper T cell) ...
(Date:5/21/2013)... May 21, 2013 U.S. spending on specialty ... diseases such as cancer, multiple sclerosis and rheumatoid arthritis ... end of 2015, according to a forecast released today ... http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we see ... health plans to act so they can continue to ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... ACRX ), a specialty pharmaceutical company focused ... therapies for the treatment of acute and ... that in a placebo-controlled Phase 3 study ... (patient-controlled analgesia) System (NanoTab System), the primary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
Cached News: